OncoHost to Present Proteomics-Based Biomarker Model for Clinical Benefit to Immunotherapy in NSCLC Patients at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, has developed a novel predictive model for clinical benefit of immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients. The model is based on proteomic profiling of pre-treatment blood samples, combined with machine learning analysis, that accurately predicts clinical benefit probability at twelve months, outperforming the predictive capabilities of the existing PD-L1 biomarker. The study was conducted using OncoHost’s first-of-its-kind PROphet® platform, and will be presented as a poster at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting (which is being held November 8-12, in Boston). The OncoHostposter will be presented in the poster hall at SITC on November 10 and 11, 2022, between 9:00 and 21:00 EST and will be available in the Journal for Immunotherapy of Cancer (JITC) supplement. This information was provided in a news release posted by OncoHost on November 7, 2022.

Login Or Register To Read Full Story